biostudies-literaturePifer PMNCI NIH HHS148-153https://www.ebi.ac.uk/biostudies/studies/S-EPMC11225593biostudies-literatureUnknown117(1)<h4>Purpose</h4>Lymphovascular space invasion (LVSI) predicts for higher rates of recurrence and increased mortality in endometrial cancer. Using 3-tier LVSI scoring, a PORTEC-1 and -2 trials analysis demonstrated that substantial LVSI was associated with worse locoregional (LR-DFS) and distant metastasis disease-free survival (DM-DFS), and these patients possibly benefited from external beam radiation therapy (EBRT). Furthermore, LVSI is a predictor for lymph node (LN) involvement, but the significance of substantial LVSI is unknown in patients with a pathologically negative LN assessment. We aimed to evaluate clinical outcomes of these patients in relation to the 3-tier LVSI scoring system.<h4>Methods and materials</h4>We performed a single-institutional retrospective review of patients International journal of radiation oncology, biology, physicsIs Substantial Lymphovascular Space Invasion Prognostic in Patients With Pathologically Lymph Node-Negative Endometrial Cancer?PMC11225593P30 CA047904Vargo JAEdwards RCourtney-Brooks MCohen MJaishankar STaylor SBhargava ROlawaiye AKeller ABeriwal SMusunuru HBSukumvanich PBerger JLLesnock JSchad MDPifer PMBoisen MfalseIs Substantial Lymphovascular Space Invasion Prognostic in Patients With Pathologically Lymph Node-Negative Endometrial Cancer?<h4>Purpose</h4>Lymphovascular space invasion (LVSI) predicts for higher rates of recurrence and increased mortality in endometrial cancer. Using 3-tier LVSI scoring, a PORTEC-1 and -2 trials analysis demonstrated that substantial LVSI was associated with worse locoregional (LR-DFS) and distant metastasis disease-free survival (DM-DFS), and these patients possibly benefited from external beam radiation therapy (EBRT). Furthermore, LVSI is a predictor for lymph node (LN) involvement, but the significance of substantial LVSI is unknown in patients with a pathologically negative LN assessment. We aimed to evaluate clinical outcomes of these patients in relation to the 3-tier LVSI scoring system.<h4>Methods and materials</h4>We performed a single-institutional retrospective review of patients 2023-01-01T00:00:00Z2023 Sep2025-04-05T18:35:10.062Z2025-04-05T18:35:10.062ZS-EPMC112255933689381810.1016/j.ijrobp.2023.02.053